A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology groups across North America, was led by researchers at Washington University School of Medicine in St. Louis.
Although health care organizations differ in their recommendations for use of prostate-specific antigen testing for prostate cancer screening, they agree that the decision to undergo PSA testing should be shared by patients and clinicians.
Although the digital rectal exam is widely used in primary care to screen for prostate cancer, a new study finds limited data to support its effectiveness.
Resource use intensity for patients in the targeted group was lower in both higher-cost, acute settings such as inpatient and ER as well in the lower acuity outpatient setting, compared to control patients.
These findings led them to hypothesize that antibodies generated against the C-terminus Shh epitope can bind and neutralize full-length Shh found exclusively on the CSC population, while leaving the cleaved N-terminus Shh, important for physiologic Shh signaling, unperturbed.
Scientists reported the development of a robust procedure for whole-genome copy number profiling of circulating tumor cells (CTCs) from a blood test. In contrast to existing methods that are complex and costly, the single-tube, single-step protocol detect absolute copy number alterations (CNA) in single cells and maintain accuracy at a lower cost than conventional genomic analysis procedure, opening up to the possibility for genome-driven targeted therapy selection and monitoring of disease progression in liquid biopsy.
Many men receiving prostate specific antigen (PSA) testing do so without a comprehensive shared decision making process, contrary to current guidelines.
A new model developed by Michigan Medicine researchers could change treatment guidelines for nearly two-thirds of men with localized prostate cancer.
Inviting men with no symptoms to a one-off PSA test for prostate cancer does not save lives according to results from the largest ever prostate cancer trial conducted over 10 years by Cancer Research UK-funded scientists and published today (Tuesday) in JAMA.
A screening program that invited men to a clinic to undergo a single prostate-specific antigen (PSA) test increased detection of low-risk prostate cancer but made no significant difference in prostate cancer deaths after 10 years.